A two-year trial found that Aptivus, a protease inhibitor from Boehringer Ingelheim, was safe and effective in HIV-infected children and adolescents who took other treatments for the condition. The study, which covered 26 sites in the U.S., Europe and Latin America, showed that patients who received a combination of Aptivus and ritonavir, another HIV drug, had decreased virus levels.

Full Story:
Bloomberg, Forbes

Related Summaries